亚盛医药是一家立足中国的全球细胞凋亡靶向创新药物研发公司,细胞凋亡领域国际权威,特别是针对蛋白-蛋白相互作用靶点的核心新药研发技术在全球领先,拥有100多项全球专利,全面布局针对恶性肿瘤、乙肝、衰老性疾病等领域的治疗,构建平衡、风险可控的丰富产品管线,已有6项原创一类新药分别进入到中国、美国及澳大利亚的I-II期临床开发阶段,2016年底成功完成B轮融资5亿人民币。 Ascentage is a China based, global leading apoptosis-targete********drug discovery an******** company for global markets.A global pioneer inapoptosis-targete******** research an********, with proprietarytechnologies in developing drugs against highly challengingprotein-protein interaction展开详情
亚盛医药是一家立足中国的全球细胞凋亡靶向创新药物研发公司,细胞凋亡领域国际权威,特别是针对蛋白-蛋白相互作用靶点的核心新药研发技术在全球领先,拥有100多项全球专利,全面布局针对恶性肿瘤、乙肝、衰老性疾病等领域的治疗,构建平衡、风险可控的丰富产品管线,已有6项原创一类新药分别进入到中国、美国及澳大利亚的I-II期临床开发阶段,2016年底成功完成B轮融资5亿人民币。 Ascentage is a China based, global leading apoptosis-targete********drug discovery an******** company for global markets.A global pioneer inapoptosis-targete******** research an********, with proprietarytechnologies in developing drugs against highly challengingprotein-protein interaction targets with over 100 internationalpatents.A robust an********-balance******** of novel small molecules foraddressing great unmet medical needs in hard-to-treat cancers, hepatitisB an********-relate********.Six NCE compounds have been grante********Approvals by the FDA, CFDA or TGA an******** into Phase I or II clinicaltrials.$72 million raise******** Series B financing at the en******** 2016.收起